Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
20 04 2020
Historique:
received: 23 03 2020
revised: 15 04 2020
accepted: 16 04 2020
entrez: 25 4 2020
pubmed: 25 4 2020
medline: 17 3 2021
Statut: epublish

Résumé

Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable. Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer therapy that combines the specificity of antibodies for targeting tumors with toxicity induced by the photoabsorber after exposure to NIR-light. In this study, we developed a new phototherapy targeting podoplanin (PDPN) for MPM with the use of both NIR-PIT and an anti-PDPN antibody, NZ-1. An antibody-photosensitizer conjugate consisting of NZ-1 and phthalocyanine dye was synthesized. In vitro NIR-PIT-induced cytotoxicity was measured with both dead cell staining and luciferase activity on various MPM cell lines. In vivo NIR-PIT was examined in both the flank tumor and orthotopic mouse model with in vivo real-time imaging. In vitro NIR-PIT-induced cytotoxicity was NIR-light dose dependent. In vivo NIR-PIT led to significant reduction in both tumor volume and luciferase activity in a flank model (

Identifiants

pubmed: 32326079
pii: cells9041019
doi: 10.3390/cells9041019
pmc: PMC7225918
pii:
doi:

Substances chimiques

Gp38 protein, mouse 0
Immunoconjugates 0
Membrane Glycoproteins 0
PDPN protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Ann Glob Health. 2014 Jul-Aug;80(4):257-62
pubmed: 25459326
Cancer Lett. 2015 Aug 28;365(1):112-21
pubmed: 26021765
Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):411-3
pubmed: 20436345
Mol Biosyst. 2016 Oct 20;12(10):3046-56
pubmed: 27452807
J Immunol. 2013 Jun 15;190(12):6239-49
pubmed: 23690472
J Clin Oncol. 2018 May 1;36(13):1343-1373
pubmed: 29346042
Respiration. 2018;95(6):405-413
pubmed: 29421798
Front Oncol. 2020 Jan 24;9:1519
pubmed: 32039010
Mol Cancer Ther. 2015 Jan;14(1):141-50
pubmed: 25416790
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1301-7
pubmed: 16979138
EBioMedicine. 2020 Feb;52:102632
pubmed: 31981983
PLoS One. 2014 Nov 17;9(11):e113276
pubmed: 25401794
Ann Glob Health. 2014 Sep-Oct;80(5):393-411
pubmed: 25512155
Sci Transl Med. 2016 Aug 17;8(352):352ra110
pubmed: 27535621
Med J Aust. 2011 Sep 5;195(5):271-4
pubmed: 21895596
Bioconjug Chem. 2016 Feb 17;27(2):404-13
pubmed: 26444497
J Vis Exp. 2016 Mar 14;(109):
pubmed: 27022757
Cancer Sci. 2019 May;110(5):1653-1664
pubmed: 30801908
Arch Pathol Lab Med. 2010 Oct;134(10):1520-7
pubmed: 20923309
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
Cancer Sci. 2008 Jan;99(1):54-61
pubmed: 17944973
Cancer Immunol Immunother. 2017 May;66(5):551-564
pubmed: 28213726
Blood. 2014 Apr 17;123(16):2470-7
pubmed: 24578503
Hum Pathol. 2005 Apr;36(4):372-80
pubmed: 15891998
Adv Respir Med. 2019;87(5):289-297
pubmed: 31680229
Am J Cancer Res. 2016 Jan 15;6(2):370-86
pubmed: 27186410
Mol Oncol. 2014 May;8(3):620-32
pubmed: 24508062
Am J Surg Pathol. 2008 Jan;32(1):123-7
pubmed: 18162779
Mol Pharm. 2015 Sep 8;12(9):3303-11
pubmed: 26261913
Eur Respir Rev. 2016 Dec;25(142):472-486
pubmed: 27903668
Cancer Immunol Immunother. 2015 Jan;64(1):113-21
pubmed: 25314912
Lung Cancer. 2018 Oct;124:260-269
pubmed: 30268471
Sci Rep. 2014 Aug 01;4:5924
pubmed: 25080943
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
Bioconjug Chem. 2017 May 17;28(5):1458-1469
pubmed: 28402624
Br Med Bull. 2010;93:105-23
pubmed: 20047972
Theranostics. 2015 Mar 19;5(7):698-709
pubmed: 25897335
Mol Biol Cell. 2011 Sep;22(17):3103-19
pubmed: 21775625
ACS Cent Sci. 2018 Nov 28;4(11):1559-1569
pubmed: 30555909
Clin Cancer Res. 2019 Sep 15;25(18):5485-5492
pubmed: 31164373
Int J Oncol. 2013 Jun;42(6):1849-57
pubmed: 23588876
RSC Adv. 2015 Mar 3;5(32):25105-25114
pubmed: 25866624
Int J Mol Sci. 2019 Feb 06;20(3):
pubmed: 30736372
Am J Respir Crit Care Med. 2017 Aug 1;196(3):274-282
pubmed: 28252315
Carcinogenesis. 2009 Jul;30(7):1097-105
pubmed: 19380521
Acc Chem Res. 2019 Aug 20;52(8):2332-2339
pubmed: 31335117
Cancer Sci. 2006 May;97(5):387-94
pubmed: 16630136
Oncotarget. 2015 Aug 14;6(23):19747-58
pubmed: 25992770
Oncotarget. 2016 Apr 26;7(17):23361-9
pubmed: 26981775

Auteurs

Yuko Nishinaga (Y)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Kazuhide Sato (K)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
B3-Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), Nagoya University Institute for Advanced Research, Nagoya 466-8550, Japan.
Nagoya University Institute for Advanced Research, S-YLC, Nagoya 464-8601, Japan.

Hirotoshi Yasui (H)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Shunichi Taki (S)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Kazuomi Takahashi (K)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Misae Shimizu (M)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
B3-Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), Nagoya University Institute for Advanced Research, Nagoya 466-8550, Japan.

Rena Endo (R)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
B3-Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), Nagoya University Institute for Advanced Research, Nagoya 466-8550, Japan.

Chiaki Koike (C)

Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
B3-Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), Nagoya University Institute for Advanced Research, Nagoya 466-8550, Japan.

Noriko Kuramoto (N)

B3-Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), Nagoya University Institute for Advanced Research, Nagoya 466-8550, Japan.

Shota Nakamura (S)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Takayuki Fukui (T)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Hiroshi Yukawa (H)

B3-Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), Nagoya University Institute for Advanced Research, Nagoya 466-8550, Japan.
Institute of Nano-Life-Systems, Institutes of Innovation for Future Society, Nagoya University, Nagoya 464-8601, Japan.
Department of Biomolecular Engineering, Nagoya University Graduate School of Engineering, Nagoya 464-8601, Japan.

Yoshinobu Baba (Y)

Institute of Nano-Life-Systems, Institutes of Innovation for Future Society, Nagoya University, Nagoya 464-8601, Japan.
Department of Biomolecular Engineering, Nagoya University Graduate School of Engineering, Nagoya 464-8601, Japan.

Mika K Kaneko (M)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Toyofumi F Chen-Yoshikawa (TF)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Hisataka Kobayashi (H)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1088, USA.

Yukinari Kato (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
New Industry Creation Hatchery Center, Tohoku University, Sendai 980-8575, Japan.

Yoshinori Hasegawa (Y)

National Hospital Organization, Nagoya Medical Center, Nagoya 460-0001, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH